Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study

BACKGROUND: Children aged ≥ 6 to < 12 years with severe atopic dermatitis (AD) have limited treatment options. In a 16‐week, randomized, placebo‐controlled, phase III trial in children, dupilumab, a monoclonal antibody inhibiting interleukin (IL)‐4/IL‐13 signalling, significantly improved signs a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cork, M.J., Thaçi, D., Eichenfield, L.F., Arkwright, P.D., Sun, X., Chen, Z., Akinlade, B., Boklage, S., Guillemin, I., Kosloski, M.P., Kamal, M.A., O’Malley, J.T., Patel, N., Graham, N.M.H., Bansal, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247037/
https://www.ncbi.nlm.nih.gov/pubmed/32969489
http://dx.doi.org/10.1111/bjd.19460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247037/
https://www.ncbi.nlm.nih.gov/pubmed/32969489
http://dx.doi.org/10.1111/bjd.19460

Ejemplares similares